Barilla Opens Its New Innovation Center to Drive Food Innovation Worldwide
18.11.2025 12:37:00 CET | Business Wire | Press Release
How can we bring the excellence of Italian culinary tradition into the future? How can we transform everyday products into experiences that surprise the senses, create emotions, and accompany people in moments of pleasure, sharing, and discovery? The answer for Barilla Group is the Barilla Innovation & Technology Experience (BITE) in Parma, marking the company’s most significant investment in food innovation in recent years. With almost 14,000m², more than €20 million invested and an additional €2 million per year dedicated to equipment upgrades, BITE stands as a global hub designed to foster development across the Group’s portfolio. Pasta, sauces, and bakery become a territory of exploration here, where research and technology serve Barilla's passion for good food.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118376430/en/
Guido, Paolo and Luca Barilla. © Barilla
Rooted in an approach of collaboration with leading international minds, this new Innovation Center brings together a team of 200highly skilled experts, including food technologists, researchers, engineers, designers, professional tasters and chefs, to develop the next generation of Barilla high-quality food products. Each year, 30 young talents from both Italy and abroad join Barilla’s RDQ community through dedicated internship or other post-graduate programs, with interns coming from countries such as Turkey, Belgium, Greece, and Spain over the past two years. The center is also the beating heart of an open innovation ecosystem that already has 84 active collaborations with universities and research centers in Italy and around the world.
“At Barilla, where the product has always been at the heart of everything we do, we know that a fundamental part of our work is to imagine and create quality products that must respond and adapt to people’s evolving needs,” says Guido Barilla, Chairman of the Barilla Group. “The BITE, in addition to shaping what will be the products of tomorrow, represents a very clear entrepreneurial choice. Barilla must drive and anticipate trends and be able to engage with markets that are increasingly more open and international.”
WHERE EVERY STEP OF PRODUCT DEVELOPMENT COMES TO LIFE
Deeply rooted in the heart of the Food Valley where Barilla was born, BITE operates with a global vision: this is where products for all the Group’s brands are developed, bringing the taste of Italy to more than 100 countries. The BITE brings together all stages of food innovation under one roof. Within its 4,800 m², the Innovation Center features dedicated areas for Design Thinking where brainstorms turn into product ideas, tasting and sensory research, and experimental kitchens for pasta and bakery. An additional 9,000 m² of pilot plants host advanced research laboratories and experimental production lines where Barilla’s professionals develop, test and refine new products and processes, together with designing innovative packaging solutions and applying advanced tools to ensure outstanding food quality and safety.
Here, the journey from concept to market takes shape, a process that typically spans around 2 years (and up to 10 for the more complex projects) from researching in the selection of crop varieties and selecting ingredients to recipe development and sensory testing with both expert panels and consumers.
"Innovatingmeans placing people’s desires at the center,” explains Michele Amigoni, Head of RDQ at Barilla Group. “Understanding in depth how their needs related to food and nutrition will evolve, and from there turning ideas into reality that are new, good, and sustainable. The BITE will be a center open to the world, where it will be possible to see, touch, and understand how Barilla envisions the future of food. "
At the BITE, technologies such as the electronic nose and AI-driven smart sensors optimize processes, from mapping aromatic profiles to enhancing pasta drying. 3D printing and holographic design systems enable rapid prototyping and faster development cycles, while the rugosimeter (roughness meter) precisely measures pasta texture at the micron scale, providing valuable data to refine both product quality and the sensory experience. These tools accelerate experimentation and ensure consistency, helping deliver the same Barilla quality to consumers around the world.
COLLABORATING GLOBALLY TO DRIVE INNOVATION
The BITE is the core of an international open innovation network of 84 partnerships with universities, research institutions, and organizations worldwide, from the Ludwig-Maximilians-Universität München in Germany to Purdue University in the US and Wageningen University in the Netherlands, as well as with selected agrifood and tech startups.Since 2019, Barilla’s Good Food Makers accelerator has generated over 1,200 startup applications from 41 countries and launched 28 collaborations, ranging from sustainable indoor agriculture to AI-driven logistics and ingredient traceability.
INCLUSIVE AND SUSTAINABLE SPACES
Designed with sustainability and inclusion at its core, the BITE runs on renewable electric energy and is surrounded by research areas dedicated to the development of regenerative agriculture practices. Through a partnership with Dynamo Academy an Italian social enterprise promoting inclusive design, the building features fully accessible environments, tactile maps and flexible spaces, ensuring a welcoming experience for all.
BARILLA INNOVATION & TECHNOLOGY EXPERIENCE - NUMBERS
- Investment: over €20 million + €2 million per year for plant upgrades
- Surface area: 13,800 square meters in total (4,800 square meters Innovation Center + 9,000 square meters pilot plants)
- Employment: 200 professionals + 30 young talents per year
- Network: 84 active collaborations with universities and research centers
- Tasting: over 1,000 samples tasted annually by certified experts
- Startup ecosystem: 28 active collaborations, 1,200 applications from 41 countries
View source version on businesswire.com: https://www.businesswire.com/news/home/20251118376430/en/
Contacts
Elena Botturi: elena.botturi@barilla.com, +31642472860
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom